Kornimate/medical-research-clean huggingface dataset:
reducing self-stigma among individuals with history of childhood maltreatment: a cross-cultural lens

Conditions: Stigma, Social; Child Abuse; Child Neglect; Help-Seeking Behavior

Summary: individuals who report experiencing any kind of abuse during childhood report shame and self-blame, often leading to self-stigma and a reluctance to reveal their experiences and seek help. such stigma may aggravate the mental health consequences of child maltreatment (cm). the investigators hypothesize that: 1. the brief video-based intervention will have the immediate and repeated effect of reducing self-stigma among cm survivors compared with the control condition. 2. the brief video-based intervention will increase seeking treatment compared with the control condition. 3. the brief video-based intervention will show similar effects in reducing self-stigma across multiple countries.

prior research suggests that social contact-based interventions are the most efficient way of reducing stigma. this study aims to address self-stigma and empower individuals who self-reported experiencing any kind of abuse during childhood and increase their openness to seeking help, if needed. four hundred participants with self-reported experience of any kind of childhood abuse will be recruited to participate in a randomized controlled trial (rct) testing the efficacy of the intervention. participants will be randomized into one of two arms: 1) a 2-minute video intervention in which a cm survivor (presented by an actor) shares their personal cm experience and describes how they were able to overcome feelings of shame and self-blame to seek mental health care; or 2) a 2-minute control video using the same actor, but without a personal narrative of cm experience. both videos will be preceded by and immediately followed by questionnaires assessing self-stigma and openness to seeking treatment. an additional assessment of emotional engagement will be added immediately following intervention delivery. following the intervention, there will be a 30- day follow-up to examine potential long-term effects. the results will be analyzed alongside results from parallel protocols being conducted by partner sites in other countries (switzerland, sweden, japan, peru, india, australia, turkey, south africa, and israel). each site will conduct the study under their own university's purview and with their own protocol, and only deidentified data will be shared for analysis. all study procedures will be conducted remotely via cloudreseach and mechanical turk, which is a crowdsourcing platform. the study survey will be hosted by qualtrics.

Eligibility criteria:
inclusion criteria: * age 18-80 * us resident * individuals who endorse yes to one of the following items: physical aggression in family or household, emotional or verbal abuse in family or household, sexual abuse or inappropriate sexual experiences, negligence - physical or emotional, mental illness or substance abuse at home, incarceration of family member * fluent in english and able to give informed consent exclusion criteria: - n/a
ridge preservation with provisional ovoid pontic

Conditions: Alveolar Process Atrophy

Summary: a prospective randomized controlled trial of 30 patients from the faculty of dentistry of the ufjf was conducted. it was included patients who presented indication of extraction of premolars, canines or incisors. all the thirty patients underwent dental extraction and were randomly divided into three groups according to the study methodology. plaster casts and cone-beam computed tomography (cbct) exams were performed for comparative analysis between sample groups and between study times ( imediate postoperative and four months later).

thirty consecutive patients who presented at the dentistry college of federal university of juiz de fora (brazil) were selected, requiring a single-tooth extraction of premolar, canines or incisors in maxilla. all of the patients included at this study signed a free and informed consent form, agreeing to participate voluntarily in this research. the study was approved by the research ethical committee of the university of juiz de fora under the form 1.731.395. the patients were randomly allocated in three groups according the following treatments: * group 1: closure of the socket by primary intention through a palatal pedicle subepithelial connective tissue flap by the technique of khoury \& happe (2000) (figure 1); * group 2: filling the socket with a synthetic bone substitute of biphasic calcium phosphate (bone ceramic®, straumann) and covering it with a palatal pedicle flap by the technique of khoury \& happe (2000) (figure 2); * group 3: sealing of the socket with a provisional ovoid pontic of acrylic resin (figure 3). as response factors were performed evaluations of study casts and tomographic analysis for dimensional stability evaluation of the sockets at immediate postoperative and after four months of the surgical procedures.

Eligibility criteria:
inclusion criteria: * patients with indication of extraction of premolars, canines or incisors, which has two adjacent teeth, due to root fracture, extensive caries that did not allow unfavorable restorative and / or endodontic prognosis, systemically healthy. exclusion criteria: * patients who use any drug that influences bone metabolism, patients with a history of head radiotherapy and neck, patients undergoing chemotherapy for the treatment of malignant tumors at the time of the study, patients with socket severely reabsorbed, smokers and pregnant women.
effectiveness of automated inpatient endocrinology consultation for osteoporotic hip fracture

Conditions: Osteoporosis

Summary: osteoporosis has been called a "silent epidemic" whose prevalence is increasing. it often presents as a fragility fracture, with hospitalizations resulting from minimally traumatic hip fractures. while the fractures are treated appropriately, the underlying pathology is often ignored. numerous studies have shown that prior fracture increases the risk for further fracture. in 2004 the surgeon general released a report on osteoporosis, the details of which include multi-disciplinary treatment of osteoporotic fractures. treatment of osteoporosis after hip fracture is also being targeted as a future hospital quality assessment measure. hospitals which have no plan in place to address osteoporosis treatment after hip fracture may be cited, and may have medicare money withheld. the goal of the study is to create an automated in-patient endocrinology consultation for osteoporotic hip fractures. we plan to gather patient data in a prospective manner including the endocrinologist recommendations, adherence to medical therapy after discharge, and future fracture rates. possible planned interventions include only appropriate medical therapy for osteoporosis, dexa bone scanning, and regularly scheduled telephone follow-up.


Eligibility criteria:
inclusion: 1. over 55 2. non-traumatic hip fracture exclusion criteria: 1. currently on anti-osteoporosis pharmacotherapy including bisphosphonates, pth, and calcitonin 2. high energy nature of fracture, including mva, fall from height greater than 3 feet 3. severe dementia, lack of capacity

Keywords: the main objective is to have an endocrinologist treat osteoporosis in patients with fragility hip fractures.
evaluation of two different thickening products in patients with dysphagia

Conditions: Dysphagia

Summary: dysphagia is extremely common. the importance of providing adequate nutritional support to persons with dysphagia is the cornerstone to exceptional care. diet modification with thickening agents is an essential aspect of this nutritional support. the purpose of this investigation is to compare the efficacy of a starch based (thickenup or tu) to a gel based thickening agent (thickenup advance or tua).

swallowing problems (dysphagia) are encountered frequently in primary practice and in the hospital setting. the list of possible causes is large, ranging from strokes and neurological disease to complications of cancer treatment, acid reflux, and surgery. many patients have a reduced ability to feel food and fluid (reduced sensation) within the throat (pharynx) and this leads to an inability to manipulate food and fluids in the correct manner. this can produce a variety of swallowing problems such as choking on foods and fluids, regurgitation, aspiration, weight loss, malnutrition and poor quality of life. treatment of dysphagia is largely directed at rehabilitation of muscle power and education about safe swallowing techniques or positioning that limits food and fluid from entering the airway. one of the most widely accepted treatments of dysphagia is to alter the texture of food. most patients with dysphagia will have more difficulty swallowing thin liquids. by adding a thickener to the liquid, a food bolus becomes more cohesive, and is less likely to become aspirated. various types of thickening products are available over-the-counter without a prescription. these thickening products are bland and currently have no flavor. the investigators hypothesize that alterations in food taste (sweet, salty, etc...), viscosity will improve swallowing efficiency. the purpose of this investigation is to evaluate the effects of food taste, texture on swallowing efficiency. the goal is to develop safer, better tasting food products and improve the quality of life in patients with disabling swallowing disorders.

Eligibility criteria:
inclusion criteria: * history of dysphagia necessitating a dynamic fluoroscopic swallow study * age \> 18 years * ability to complete a comprehensive dynamic fluoroscopic swallow study * ability to provide informed consent for study participation exclusion criteria: * age \< 18 years * pregnant women * prisoner or other institutionalized individual * cognitive disability precluding the ability to provide informed consent or complete a comprehensive swallow study

Keywords: dysphagia thickening liquid thickening agent fluoroscopic swallow study aspiration history of dysphagia dss age > 18 comprehensive dss informed consent
feasibility randomized trial for an intensive memory-focused training program for school aged children with acquired br.inj.

Conditions: Acquired Brain Injury

Summary: memory deficits are common sequelae of pediatric acquired brain injury (abi). only methods for non-focused cognitive remediation are available to the pediatric field. the aims of this feasibility trial are the description, implementation, and test of an intensive program specific to the training and re-adaptation of memory function in children (im-ftp). method: eleven children and adolescents with abi (mean age at injury=12.2 years, brain tumor survivors excluded) were clinically assessed and rehabilitated over 1-month through im-ftp, including physio-kinesis/occupational, speech, and neuropsychology treatments. each patient received a psychometric evaluation and a brain functional mri at enrollment and at discharge. ten pediatric controls with abi (mean age at injury=13.8 years) were clinically assessed, and rehabilitated through a standard program.


Eligibility criteria:
inclusion criteria: * i) age at first assessment between 6 and 18 years; * ii) time between injury and first assessment \<3 months; * iii) documented evidence of a severe abi of traumatic or non-traumatic (i.e. anoxic, vascular or infectious) etiology, as indicated by a glasgow coma scale (gcs, \[26\]), score ≤8 at insult; * iv) presence of severe memory impairment, as assessed at first evaluation; * v) sufficient attentive skills for attending a simple task and understanding simple commands/directions, and sufficient verbal comprehension for executing simple procedures/exercises; * vi) absence of congenital pathology or disability previous to the injury; * vii) medical records sufficiently detailed to determine the injury severity and neurological findings; * viii) absence of severe motor or sensitive deficits. exclusion criteria: * none
powermom, a healthy pregnancy research community

Conditions: Pregnancy Related; Weight Change, Body; Health Problems in Pregnancy; Behavior

Summary: this study will take advantage of the open source framework of researchkit developed by apple to bring research directly to participants. using the researchkit platform as well as a stand alone app available for android and html, it makes it easier to enroll large numbers of participants and carry out real-world health research to answer questions important to a broad population.

* eligibility determined, individuals enrolled and consented to join study * short intake survey (demographic and baseline health information collected) * health history survey (two days after participant enrolls in the study) * survey questions about current health and medical history will be sent to participants weekly. if participants had a prenatal visit during the week, a few additional questions will be asked. * twins / multiples survey will begin appearing when a participant indicates they are having more than one baby * participants can submit home measurements of, weight and blood pressure as frequently as they want through healthkit. * pregnancy outcome variables. (miscarriage, stillbirth, birth of healthy baby, or pregnancy ended) will also be asked weekly. * if the baby is born, questions about labor and delivery, as well as weight, size and birth date of the baby will be asked. a reminder to fill out the outcome survey will be given 4 weeks after a user's due date.

Eligibility criteria:
inclusion criteria: * adults, 16 years of age or older * pregnant women or within 8 weeks postpartum * currently live within the united states * own, and comfortable using, a smartphone or tablet exclusion criteria: • inability to consent

Keywords: weight change healthy pregnancy physiologic sensors
diabetes resolution and hormone changes after bpdll and lsg

Conditions: Diabetes Mellitus

Summary: to evaluate and compare prospectively the effects of biliopancreatic diversion long limb (bpdll) and laparoscopic sleeve gastrectomy (lsg) on resolution of diabetes mellitus type 2.

twelve patients with diabetes mellitus type 2 (dm 2) and body mass index (bmi)\> 50kg/m2) will undergo bpdll and 12 twelve patients with dm 2 and bmi 40-50 kg/m2 will undergo lsg. the patients will be evaluated before and 1, 3 and 12 months after surgery with an oral glucose tolerance test. the investigators aim to investigate the effects of surgery on diabetes resolution, hypertension, dyslipidemia, and also on fasting, and glucose-stimulated insulin, glucagon, ghrelin, peptide-yy and glucagon-like peptide-1 (glp-1) responses during during an oral glucose tolerance test (ogtt). resolution of diabetes mellitus will be evaluated according to the criteria of american diabetes association with an ogtt. the effects on appetite and satiety will be also evaluated with the use of visual analog scores.

Eligibility criteria:
inclusion criteria: * bmi\>50kg/m2 to undergo bpdll * bmi 40-50kg/m2 to undergo lsg * diabetes mellitus type 2 exclusion criteria: * chronic medical illness * psychiatric illness * substance abuse * previous gastrointestinal surgery

Keywords: biliopancreatic diversion sleeve gastrectomy diabetes mellitus weight loss ghrelin pyy glp-1
cerebellar deep brain stimulation for movement disorders in cerebral palsy in children and young adults

Conditions: Dyskinetic Cerebral Palsy; Dystonic Cerebral Palsy

Summary: the purpose of this study is to test the safety of placing deep brain stimulators (dbs) in a part of the brain called the cerebellum and using electrical stimulation of that part of the brain to treat movement symptoms related to cerebral palsy. ten children and young adults with dyskinetic cerebral palsy will be implanted with a medtronic percept primary cell neurostimulator. we will pilot videotaped automated movement recognition techniques and formal gait analysis, as well as collect and characterize each subject's physiological and neuroimaging markers that may predict hyperkinetic pathological states and their response to therapeutic dbs.


Eligibility criteria:
inclusion criteria: * diagnosis of dcp (dystonic and/or choreoathetotic cerebral palsy) with or without comorbid spasticity, with a clear history of hypoxic ischemic brain injury preceding motor symptoms made by a pediatric neurologist, with supporting mri findings. * age 7-25 at the time of surgery. * gross motor function classification system (gmfcs) levels ii-v. * history of appropriate therapy with oral medications with inadequate relief as determined by a movement disorders or pediatric neurologist. prior history of selective dorsal rhizotomy is allowed. * patient and family have requested surgical intervention with dbs for their movement disorder. * no gross cerebellar abnormalities observed and reported on structural mri. * written informed consent and written/verbal assent for those younger than 18 years of age. * ability to comply with study follow-up visits for brain recordings, neuroimaging and testing of sham and effective stimulation and clinical assessments. exclusion criteria: * coagulopathy, uncontrolled epilepsy, severe cardiopulmonary or gastrointestinal conditions, or other medical conditions considered to place the patient at elevated risk for surgical complications. * pregnancy: all women of child-bearing potential will be required to have a negative urine pregnancy test prior to undergoing their surgical procedure. * exclusion of genetic mimics of cerebral palsy: exclusion of conditions that manifest with a clinical syndrome similar to cp, in the absence of documented risk factors or neuroimaging findings consistent with a history of brain injury or congenital cerebral malformation. work up may include comparative genomic hybridization (cgh) microarray and multi-gene panel and/or whole genome or whole exome sequencing.) * severe fixed contractions and skeletal deformities that would preclude determination of improvement. * traumatic brain injury (i.e., non-accidental trauma) or history of infectious or autoimmune encephalitis. * requirement of diathermy, electroconvulsive therapy or transcranial magnetic stimulation.
o-live: impact of a portuguese olive oil in health biomarkers

Conditions: Adult Healthy Volunteers

Summary: this research project, approved and funded, is part of a larger project, entitled "healthy soil for food", which completes several work packages, one of which is a clinical research submitted to ethics committee entitled "o-live: impact of olive oil portuguese in biomarkers of healthy volunteers". the main objective of this work is to evaluate the impact of ingestion of an olive oil rich in polyphenols on clinical biomarkers and parameters, such as anthropometric measurements, on inflammatory gene expression regulation and on the composition of the intestinal microbiota.

olive oil is an ancient product that is crucial for social cohesion and for local economies in the mediterranean region, particularly in portugal. there is ample evidence on the protective effect of olive oil in cardiovascular disease, diabetes, oncological diseases and neurological degeneration. furthermore, olive oil has been shown to increase the rate of oxidation, inhibiting lipogenesis and stimulating lipolysis, in addition to affecting the expression of receptors involved in weight regulation and fat use. these health benefits of olive oil derive from its specific nutritional composition, with monounsaturated fatty acids, polyphenols and phenolic compounds, which act on metabolism, modulation of inflammatory responses and gene expression. but the composition of olive oil can vary considerably depending on the type of cultivation of olive trees, soil management practices, as well as the extraction and technological processes involved in olive oil production. in this work the investigators will use an olive oil rich in polyphenols (produced in a sustainable and local manner) and evaluate its effect on several important clinical parameters involved in chronic diseases. the investigators anticipate that the results of this work will help support the relationship between consuming higher polyphenol olive oil and improved overall health.

Eligibility criteria:
inclusion criteria: * healthy volunteers exclusion criteria: * current active infections * medications (antidepressant medication, antibiotics, anti-inflammatory, angiotensin converting enzyme inhibitors, insulin and oral anti-diabetic medication) * dietary supplements (minerals and oligoelements, antioxidants, n-3 polyunsaturated fatty acids, n-6 polyunsaturated fatty acids, n-9 fatty acids) * presence of ant chronic/metabolic diseases: * diabetes * cancer * inflammatory diseases

Keywords: olive oil inflammation gut microbiota mediterranean diet
shr-a1811 combination regimen for the treatment of recurrent or metastatic cervical cancer

Conditions: Recurrent or Metastatic Cervical Cancer

Summary: this study is a multicentre, open-label, dose-finding/efficacy-expanding phase ib/ii clinical trial to evaluate the tolerability, safety, pharmacokinetic profile and immunogenicity of shr-a1811 combination regimen in the treatment of recurrent or metastatic cervical cancer and to preliminarily evaluate the efficacy of shr-a1811 combination regimen for recurrent or metastatic cervical cancer.


Eligibility criteria:
inclusion criteria: 1. subjects must voluntarily join this study, sign the informed consent form, have good compliance and be able to cooperate with the follow-up. 2. female, aged 18-75 years old. 3. expected survival ≥ 12 weeks. 4. normal function of vital organs. 5. female subjects of childbearing potential must have a negative serum hcg test within 7 days prior to the first dose and must be non-lactating. 6. female subjects must agree to comply with contraceptive requirements from signing the informed consent form to 7 months after the last dose of the investigational drug. exclusion criteria: 1. previous or concomitant other malignancies. 2. severe bone damage caused by bone metastasis from tumours. 3. presence of active autoimmune disease or history of autoimmune disease with possible recurrence. 4. those with active tuberculosis. 5. concomitant poorly controlled or severe cardiovascular disease. 6. occurrence of arteriovenous thrombotic events within 6 months prior to the first dose. 7. presence of gastrointestinal obstruction or presence of symptoms and signs of gastrointestinal obstruction within 6 months prior to the first dose. 8. subjects who have had a serious infection within 1 month before the first dose. 9. subjects who have a history of immunodeficiency. 10. as judged by the investigator, there are other factors that may affect the results of the study or cause the study to be forced to terminate halfway.